Recruitment has been completed in Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease focal segmental glomerulosclerosis. ... Read More The post Pre-Christmas milestone for Dimerix as ACTION3 phase III fully recruited appeared first on Stockhead .